p53 expression in cytology samples may represent a marker of early‐stage cancer
Open Access
- 27 March 2023
- journal article
- research article
- Published by Wiley in Cancer Cytopathology
- Vol. 131 (6) , 392-401
Abstract
Background: TP53 gene plays a major role in the negative control of cell proliferation and in the regulation of signaling cascades. TP53 mutation may have a relevant role in the malignant transformation of thyroid cells as well as thyroid tumor progression. TP53 mutation has been detected only in few well differentiated thyroid carcinomas and is absent in benign conditions. Methods: A total of 162 prospective thyroid cytology and corresponding histological samples diagnosed from atypia of indeterminate significance (AUS) to malignant, were studied via immunocytochemistry for p53. Hence, 50 benign lesions (B) were used as negative control. Molecular analysis for p53 only was performed. Results: The cytology resulted in 50 B, 48 AUS, 40 follicular neoplasms (FNs), 23 suspicious for malignancy (SFM), and 1 malignant (M) case. The authors reported 102 negative and 60 positive p53 cases. The 60 positive cases included 27 cases with weak and/or focal cytoplasmic positivity (+1) and 33 with cases moderate (2+) to strong (3+) cytoplasmic and/or nuclear expression. Overall, 71 cases had histology (2 B, 11 AUS, 37 FN, 20 SFM, and 1 M) including 61.7% benign and 38.2% malignant diagnoses. Only 16 of 71 (5 FN, 10 SFM, and 1 M) were p53‐positive. Furthermore, 100% AUS and 86.5% FN cases were p53‐negative, none of which had malignant histology. All p53‐positive cases were associated with a larger nodule size, tall‐cell variant subtype, multifocality, extra thyroidal infiltration, and nodal metastases. Noninvasive follicular thyroid neoplasm with papillary like nuclear features were negative for p53. Few discrepancies in p53 intensity were observed on histology; there were no differences with the molecular testing. Conclusions: p53 might be useful in discriminating thyroid follicular lesions. p53 is likely to be a useful diagnostic marker in recognizing indeterminate lesions that are well‐differentiated thyroid cancers.Keywords
This publication has 25 references indexed in Scilit:
- Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experienceCancer Cytopathology, 2014
- Worldwide Increasing Incidence of Thyroid Cancer: Update on Epidemiology and Risk FactorsJournal of Cancer Epidemiology, 2013
- BRAF (V600E) mutation analysis on liquid‐based cytology‐processed aspiration biopsies predicts bilaterality and lymph node involvement in papillary thyroid microcarcinomaCancer Cytopathology, 2012
- BRAF Mutation in Papillary Thyroid Cancer and Its Value in Tailoring Initial TreatmentMedicine, 2012
- Liquid-Based Cytology in Fine-Needle Aspiration Biopsies of the Thyroid GlandActa Cytologica, 2011
- Molecular genetics and diagnosis of thyroid cancerNature Reviews Endocrinology, 2011
- Comparison of proliferating cell nuclear antigen, thyroid transcription factor-1, Ki-67, p63, p53 and high–molecular weight cytokeratin expressions in papillary thyroid carcinoma, follicular carcinoma, and follicular adenomaAnnals of Diagnostic Pathology, 2011
- Prognostic utility of BRAF mutation in papillary thyroid cancerMolecular and Cellular Endocrinology, 2010
- Expression of p53, c-erbB-2 and Ki67 in intestinal metaplasia and gastric carcinomaWorld Journal of Gastroenterology, 2010
- BRAF mutation in thyroid cancerEndocrine-Related Cancer, 2005